Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

410 Study Matches

Investigation of Semantic Processing in Context

The purpose of this study is to investigate the effects of context on the processing of words in young adults with and without an autism spectrum disorder. The knowledge gained may lead to further understanding of the cognitive and linguistic processing of individuals with autism spectrum disorder—how they understand and see the world around them. The study is being conducted at our on-campus lab and includes the completion of some standardized paper and pencil tests and some computer-based activities. Participants receive compensation for their participation.
DIANE WILLIAMS at dlw81@psu.edu or 814-865-3177
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Speak English as primary language
Normal or corrected to normal vision
Normal hearing
With or without a diagnosis of an autism spectrum disorder or Asperger syndrome
Exclusion Criteria:
Cannot speak sentence length English
Vision problems (uncorrected)
Hearing problems
Mental & Behavioral Health, Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Reducing Perception Error in Diagnostic Radiology

This research is being done to find out the relationship between an individual’s mental state and how well they perform visual-perceptual tasks. This will allow us to understand the brain processes related to errors in image perception, to understand how mental states impact medical image interpretation. Overall, this research will help us develop training programs to reduce the amount of perceptual errors in diagnosing images
Lauren Spreen at lspreen@pennstatehealth.psu.edu or 717-531-5857
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Radiologists with different levels of experience
Healthy adults, with college or advanced degree
Normal or corrected to normal vision
Exclusion Criteria:
Non-English speaking
Pregnant or lactating
Presence of pacemaker, aneurysm clips, or any metal in the body
A history of welding or grinding
Claustraphobia
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Non-invasive sampling method of respiratory exhaled breath condensate (EBC) and nasal mucosa for smoking related biomarkers

The objective of this preliminary study is to collect EBC samples from 20 healthy volunteers for use in the measurement of specific tobacco related biomarkers of exposure and oxidative stress. Laboratory studies will also be conducted to detect specific markers and to determine their variability and stability and establish optimal collection and processing protocols
Reema Goel at rgoel@phs.psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Able to understand and provide consent
Exclusion Criteria:
1. Unstable or significant medical conditions that affect oxidative stress
Addiction & Substance Abuse, Prevention
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium(BTCRC-GU16-043) (PSCI 18-008)

This study is being done to test the safety of combining durvalumab with guadecitabine. It will also measure the percentage of patients whose tumor shrank after receiving durvalumab in combination with guadecitabine. Participants with kidney cancer that has spread to other parts of the body, also known as 'metastatic kidney cancer' will be recruited to participate.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03308396
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histological diagnosis of clear cell renal cell carcinoma (pure or mixed) with radiologic or histologic evidence of metastatic disease
Prior cancer treatment must be completed at least 14 dats prior to study registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade 1 or less baseline
ECOG Performance Status 0-1 within 28 days prior to registration
Demonstrate adequate organ function based on necessary screening labs to be obtained within 28 days prior to registration
Females of childbearing potential must have a negative serum pregnancy test within 28 days prior to registration
Exclusion Criteria:
Active infection requiring systemic therapy
Brain metastases or spinal cord compression
Pregnant or breastfeeding
Treatment with any investigational drug within 14 days prior to study registration
Current or prior use of immunosuppresive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiologic doses
Kidney & Urinary System, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Asymmetric neurodegeneration of central olfactory system in early-stage Parkinson’s disease

This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with H&Y stage 1 or 2 Parkinson’s disease compared to that of healthy volunteers.
Lauren Spreen at lspreen@pennstatehealth.psu.edu or 717-531-5857
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cognitively-normal H&Y stage 1 PD patients. A physician-documented parkinsonian symptom onset between the ages of 40-59. 1st visit prior to age 65. PD stage I diagnosis must be documented for a min of 2 years.
Cognitively-normal H&Y stage 2 PD patients. H&Y stage 2, as defined by an exam in the practically defined “off” state, and have a diagnosis of PD at the age of 59 or younger. 1st visit prior to age 65
Healthy participants between ages 40-64 at their first visit.
Able and willing to provide informed consent
Fluent in written and spoken English
Exclusion Criteria:
Parkinson-plus syndrome
Dementia
Previous antipsychotic or anti-dopamine drug therapy
Traumatic head injury
Other neurological diseases or disorders
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For COMET-PCOS

Site For COMET-PCOS
Patsy Rawa at prawa@pennstatehealth.psu.edu or 717-531-3692
Female
18 year(s) or older
This study is also accepting healthy volunteers
NCT03229057
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Polycystic ovary syndrome (PCOS)
BMI >=25 to <=45
In good general health
Willing to avoid pregnancy for duration of study
Exclusion Criteria:
Currently pregnant or desire of pregnancy
Currently breastfeeding
Untreated thyroid disease
Untreated hyperprolactinemia
Type 1 or Type 2 diabetes
Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For AbbVie- HS Surgery

Site For AbbVie- HS Surgery
Logan Claar at lclaar@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be able to travel to Hershey Medical Center for 12 visits
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Exclusion Criteria:
Prior treatment of Humira or other biologics for the treatment of HS
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For 18-047, EA9152 Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL

Site For 18-047, EA9152 Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03504644
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Relapsed or refractory B-cell or T-cell ALL after multi-agent chemotherapy(≥ 5% marrow lymphoblasts, assessed by morphology and flow cytometry
ECOG performance status 0-2
Creatinine clearance of at least 50 mL/min within 7 days prior to first dose of study agent
Adequate liver function with AST/ALT less than 3X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent
Circulating WBC count must not be above 20 x10^9/L within 7 days prior to first dose of study agent
Exclusion Criteria:
Pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol
Evidence of isolated extramedullary relapse (i.e., testicular or CNS)
Serious medical or psychiatric illness that in the opinion of the primary investigator is likely to interfere with study participation may not be enrolled
Poorly controlled HIV, or CD4 < 400. HIV positive patients are allowed on this study if they have a CD4 count greater than or equal to 400, and are on a stable antiviral regimen
Patients with NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia may not be enrolled
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

This study is for patients 40-80 years of age with IPF (idiopathic pulmonary fibrosis). This study is being done to learn more about an experimental medication which is being developed to treat fibrosis or scarring of the lungs. The purpose of this study is to evaluate the safety of this experimental medication when administered at two dose levels compared with placebo (injection containing no active medication).
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03538301
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 40-80 years of age
Have a diagnosis of IPF within the past 5 years
Unchanged dose of pirfenidone or nintedanib for at least 12 weeks if currently taking these medications
Exclusion Criteria:
Respiratory exacerbation or hospitalization in the last 3 months
Taking both pirfenidone and nintedanib simultaneously in the past 12 weeks
Lung transplant anticipated during the study
Known history of liver cirrhosis
Active smoker or cessation in the past 12 weeks
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306)

This study is for patients with moderate to severe Crohn's disease. This research is being done to determine whether an investigational drug is safe and effective when compared to placebo (a treatment that does not contain active drug) in the treatment of patients with moderate to severe Crohn's disease.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03566823
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Crohn's disease for 3 months
Ages 18-80
Exclusion Criteria:
History of other forms of colitis
History of colon polyps (if removed may be eligible) or cancer
Past medical history of toxic megacolon
Current symptomatic diverticulitis or diverticulosis
Past medical history of multiple small bowel resections
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

This is a Phase 3 study, which means that BIIB093 (study drug) has already been investigated in previous clinical research studies with a small number of people with large hemispheric infarction (LHI). These studies suggested that the study drug was safe, did not cause serious side effects or discomfort, and may reduce brain swelling, disability, and death in subjects with LHI. In this study, we want to investigate the study drug in a larger number of subjects (hundreds) to know more about it. LHI is a type of stroke. An ischemic stroke occurs when blood flow to parts of the brain is blocked, such as by a blood clot. This can cause damage to the brain. In LHI a large portion of the brain is damaged. People who have LHI can develop swelling of the brain called cerebral edema, which can worsen the symptoms and outcomes of LHI. Currently, there are no medications available to specifically reduce brain swelling caused by LHI. In this study, we want to investigate how well the study drug works to improve functional outcomes (the ability to do normal daily activities, such as walking and getting dressed) in subjects with LHI. This study will also look at the long-term effects of the study drug over time and see how safe the study drug is.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02864953
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A clinical diagnosis of acute ischemic stroke in the MCA territory within 10 hours of symptom onset
Aged 18 to 85 years old, inclusive, at the time of informed consent
Screening NIHSS ≥10
Exclusion Criteria:
In the judgment of the Investigator, the subject is likely to have supportive care withdrawn in the first day
Commitment to decompressive craniectomy (DC) prior to enrollment
Evidence (clinical or imaging) of concurrent infarction in the contralateral hemisphere deemed by the Investigator to be sufficiently serious so as to affect functional outcome
Clinical signs of herniation and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator’s judgment
Brain hemorrhage (other than small petechial/punctate hemorrhages) on NCCT/MRI
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Immersive Virtual Reality Storm Surge: Scale and Risk Perception

Evaluating if an immersive virtual reality experience of storm surge flooding gives people an understanding of the scale of the flooding and increases their risk perception of such flooding compared to a non-immersive desktop experience.
Mark Simpson at marksimpson@psu.edu or 575-491-5512
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Normal or corrected-to-normal vision
English-speaking
Exclusion Criteria:
Under age 18
Education
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Creative Thinking and Problem Solving

This is a behavioral study that will examine cognitive processes relevant for creative thinking. Participants will be asked to complete a series of cognitive tasks and self-report measures on a computer.
James Lloyd-Cox at jll487@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
They must consent to participate in research
Healthy volunteers

Native English Speakers
Exclusion Criteria:
Cannot be non-native English speakers
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Efficacy of Virtual Reality Exposure Therapy Scripts for Social Phobia

This research is conducted to test if virtual reality technology is effective to help people face their social fears and promote the use of adaptive social skills in various settings. You will be immersed in a range of virtual reality environments and work with a research therapist to learn certain skills, such as managing fears of negative evaluation during job interviews, and interacting with peers in common social settings (e.g., classrooms, cafeterias).
Hani Zainal at nvz5057@psu.edu or 814-863-0115
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be at least 18 years old
Experiencing significant social anxiety
Able to read, write, and understand English
Not struggling with ongoing ongoing alcohol or substance use
Not actively suicidal
Exclusion Criteria:
Not interested in engaging in mental health treatment
Not socially anxious
Men's Health, Mental & Behavioral Health, Women's Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Story Circles as a Methodology: Exploring Illness Perceptions in Advanced Heart Failure

We will utilize Story Circles with persons living with advanced heart failure to explore their experiences, their illness perceptions, and how these perceptions might influence goals of care and decision making. There is a gap in our current understanding of how persons living with an advanced life-limiting illness such as heart failure perceive their illness and how this might influence decision-making. New knowledge regarding a person’s illness perceptions has important implications for future work including goals of care conversations and decision making for heart failure throughout the illness trajectory and especially at the end of life.
Lisa Kitko at lkitko@psu.edu or 814-863-2228
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or greater
Diagnosis of heart failure
English speaking
Exclusion Criteria:
Unable to provide informed consent
Heart & Vascular
  Email this study information to me
  Contact the study team
  Show all 3 locations

Study Locations

Hide all locations
Location
Altoona, PA
Hershey, PA
State College, PA

A multi-center, randomized, placebo-controlled, parallel-arm phase 2 study to investigate the efficacy, pharmakokinetics, and safety of CSL312 in subjects with Hereditary Angioedema.

This research is being done to see how safe a new investigational medication is to use and to see if the medication works to prevent HAE attacks. This study will also measure levels of drug in the blood to see how well it is tolerated.
Larisa Zifchak, RN at lzifchak@pennstatehealth.psu.edu or 717-531-4513
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03712228
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-65 (inclusive)
Clinical diagnosis of C1-INH Hereditary Angioedema
Clinical diagnosis of FXII/PLG Hereditary Angioedema
Willing to cease use of medication for routine prophylaxis against HAE attacks
Exclusion Criteria:
History of significant arterial or venous blood clotting
History of uncontrolled abnormal bleeding
Pre-planned surgeries
Known, incurable malignancies
Allergies
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial

To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with CRPC that have previously received docetaxel and ADT for HSPC can improve PFS compared to abiraterone acetate alone.
Kathleen Rizzo at kar23@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03419234
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age ≥ 18 years
Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate).
Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer.
Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/MRI of abdomen/pelvis, bone scintigraphy or NaF PET/CT).
Ability to swallow abiraterone acetate tablets as a whole.
Exclusion Criteria:
Any prior chemotherapy or AR-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone
Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate.
Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy.
Any medical condition for which prednisone (corticosteroid) is contraindicated.
Active infection requiring treatment with antibiotics.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Understanding the Relationship between Education and Well-being among College Students with Disabilities

The purpose of the study is to gain an understanding of students’ experiences in college and their engagement help-seeking and healthy behaviors. Participation in the study involves completing a brief online-survey on Qualtrics, which we anticipate will take approximately 20 minutes to complete.
Amber O'Shea at amo5208@psu.edu or 814-867-5721
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Currently enrolled as a college student
18 years of age or older
Capable of providing informed consent
Diagnosis of a disability
Able to understand written English
Exclusion Criteria:
Adults unable to provide legal consent
Individuals who are not yet legal adults
Pregnant women
Prisoners
Education, Mental & Behavioral Health, Women's Health
  Email this study information to me
  Contact the study team

A Pilot Study to Dynamic Modeling of the Effects of Physical Activity on Blood Glucose Levels in Type 1 Diabetes

This research study will help us to better understand how your blood sugar level changes when you do physical activity, especially when you do exercise. Our research team will collect data to help us understand how what you eat, your insulin dose, and what physical activity you do would affect your blood glucose level. You have to have type 1 diabetes and use an insulin pump to manage diabetes. In addition, we will have you wear a continuous glucose monitor, record the food you eat using MyFitnessPal, and wear activity monitors to track what physical activity you do over the 12- or 16-day study period. You would come to the Clinical Research Center at Penn State for your initial visit and to exercise either two times during the 12-day study period or three times during the 16-day study period. You will be compensated up to $140 for completing the entire study. If you have Type 1 Diabetes and would like to participate in this research you can contact our team at 814-863-7126 and we'll give you more details.
Christa Oelhaf at cmj108@psu.edu or 814-863-7126
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Young adult and adult individuals with Insulin Pump treated Type 1 Diabetes; ages 18-45 years living in and around Central Pennsylvania.
Well established (>6 months) in using an insulin pump to manage diabetes.
A user of Continuous Glucose Monitor (CGM) to measure interstitial glucose levels, and willingness to continue during the study.
Willingness to avoid moderate or strenuous exercise during the study, other than exercise that is part of the study.
Self reported most recent Hgb A1C < 10%.
Exclusion Criteria:
Contra-indications to engaging in exercise (i.e., health care provider has indicated no/limited activity due to a health condition – as disclosed by the subject)
Uncontrolled hypertension i.e. BP >140/90 mm Hg (ADA criterion) at the assessment visit, measured by the CRC protocol; repeat screening after potential medication adjustment by subjects health care provider is permissible.
Diagnosed significant coronary artery disease, unless written clearance by the subject’s health care provider is given.
Hypoglycemia unawareness
Currently pregnant, breastfeeding or trying to become pregnant during the likely study time frame
Diabetes & Hormones
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A more naturalistic interaction: using back-channeling in smart-speakers to indicate active listening

In this project, we aim to extend the capabilities of smart-speakers (such as Amazon Alexa, Google Home, Siri, etc.) to support more engaging interactions with their users. Specifically, we would like to make the future of smart-speakers more conversational. One of the key aspects in developing a conversation is to be an active listener; showing interest in the speaker and allowing them to extend their turn in talk. In this study we investigate how smart-speakers can become better listeners by incorporating some of the human-human conversational features of active listening. Our question is, how can smart-speakers extend the users' turn in talk by being better listeners?
Nasim Motalebi at nfm5140@psu.edu or 814-753-2081
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age and older
English speaking individuals
Exclusion Criteria:
under 18 years old
non english-speaking individuals
Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).

This is a drug study that will examine the drug Ribociclib with endocrine therapy versus just endocrine therapy in patients with early breast cancer.
Lea Russell at lmay1@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03701334
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis within 18 months prior to randomization
Patient has breast cancer that is positive for ER and/or PgR
Patient has HER2-negative breast cancer defined as a negative
Patient has available archival tumor tissue from the surgical specimen, for submission to a central laboratory.
If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines
Exclusion Criteria:
Patient has received any CDK4/6 inhibitor
Patient has received prior treatment with tamoxifen, raloxifene or AIs
Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for epirubicin.
h a known hypersensitivity to any of the excipients of ribociclib and/or ET (
Patient with distant metastases of breast cancer beyond regional lymph nodes
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)

This study is for patients with primary biliary cholangitis (PBC), which is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver, and you have been taking UDCA (ursodeoxyvholic acid) for the past 12 months or you were not able to tolerate the UDCA due to side effects. This research is being done to determine if an investigational drug, seladelpar, is safe and effective in treating patients with PBC compared to placebo (which looks like the study drug but is not active medication). This will be done by looking at how the drug affects your PBC, specifically looking into the dynamic in your laboratory parameters, such as alkaline phosphatase (AP), bilirubin, GGT (which is gamma-glutamyl transpeptidase which is a liver enzyme), and others which show severity of the disease and its prognosis. Seladelpar is an investigational drug. Investigational means that the drug has not been approved by the United States Food and Drug Administration (FDA).
Laurie Peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03602560
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of PBC
18-75 years of age
On a stable dose of UDCA for 12 months or intolerant to UDCA
Exclusion Criteria:
Presence of significant hepatic decompensation (liver failure)
History of liver transplantation or currently on transplant list
Other chronic liver disease
Known history of HIV or Hepatitis
History of alcohol or drug abuse
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

The is a drug study to compare the progression free survival of the three drug combination Ibrutinib-Obinutuzumab-Venetoclax (IOV) to Ibrutinib-Obinutuzumab (IO) in untreated CLL patients younger than 70 years of age.
Michelle Stojanovic at mstojanovic1@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03701282
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of CLL according to the NCI/IWCLL criteria or SLL according to the WHO criteria
Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy
Age ≥ 18 years and < 70.
ECOG performance status between 0-2.
Life expectancy of ≥ 12 months.
Exclusion Criteria:
No deletion of 17p13 on cytogenetic analysis by FISH
No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment.
No current use of corticosteroids.
No previous autoimmune complications
No other active primary malignancy
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Storytelling on Snapchat

This study will examine via ethnographic observation the Story feature on social media. Participants will be asked to provide their Snapchat or Instagram username and must be willing to let the researcher observe the Stories that they post. The primary aims are to illuminate how and why people are using the Story feature on social media, and to analyze how this feature is changing how we relate to and understand the world around us.
Michael Krieger at mlk75@psu.edu or 646-430-0117
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
User of the Story feature on Snapchat or Instagram
At least 18 years old
Exclusion Criteria:
Anyone under the age of 18 years old
Non users of social media
Education, Mental & Behavioral Health, Language & Linguistics
  Email this study information to me
  Contact the study team

Site for A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL.

This is a drug study with a primary outcome of testing aspirin as therapy versus a placebo pill for patients for breast cancer.
Lea Russell at lmay1@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02927249
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histologic documentation of women or men with HER2 negative breast carcinoma and free of recurrence.
Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed.
Age > 18 and < 70 years of age.
ECOG performance status 0-2.
Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can be enrolled as long as the ulcers did not cause bleeding requiring a blood transfusion/major intervention.
Exclusion Criteria:
No history of GI bleeding requiring a blood transfusion, endoscopic or operative intervention.
No history of any prior stroke (hemorrhagic or ischemic).
No concurrent anticoagulation with warfarin, heparin/heparin analogues, clopidogrel, direct thrombin inhibitors, or direct factor XA inhibitors.
No history of atrial fibrillation or myocardial infarction.
No history of grade 4 hypertension, defined as hypertension resulting in lifethreatening consequences
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Physical Activity and Recreational THC and Ethanol Use Study

This is a health behavior study that will determine if wearable sensors can be used to track physical activity and alcohol use behaviors in the context of daily life. We are interested in learning about college students' physical activity and substance use behaviors in order to inform future interventions. Participants will be asked to wear an activity monitor attached to their thigh as well as an ankle monitor that will record alcohol consumption. Participants will also complete daily questionnaires that assess a variety of health behaviors.
Ashley Sanders at abs63@psu.edu or 814-865-7935
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between ages 18-25
Enrolled at a university
Report 2 days of binge drinking in the past month, defined as 5 or more drinks for men and 4 or more drinks for women in a row
Report at least 1 day of using either tobacco or cannabis in the past year
Can participate in unassisted physical activity
Exclusion Criteria:
Report having received treatment for substance dependence
Report having a prior diagnosis of substance dependence
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Coparenting, Infant Sleep, and Infant Development: An Intervention Study

This application proposes a randomized clinical trial (RCT) to evaluate the effects of a sleep-enhanced adaptation of an evidence-based transition-to-parenting coparenting intervention program [Family Foundations - FF). The study has three arms. In one arm, families will experience FF as originally formulated; in the second, families will receive an adapted FF that emphasizes coparenting in infant sleep contexts; the third arm will serve as controls. Assessments of coparenting and parenting in infant sleep contexts, parental adjustment to infant sleep behavior, choices about sleep arrangements, infant and parent sleep quality, and infant socio-emotional functioning, will serve as outcomes.
Morgan Loeffler at FF@psu.edu or 717-695-7050
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03187561
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Parents must live together
Parents must be expecting their first baby together
We must start working with the couple before the baby is born
Parents must be 18 years or older
Families who can speak and understand English
Exclusion Criteria:
Single-parent families
Families with more than one-child
Familes who cannot speak or understand English
Families in which one parent is under the age of 18
Pregnancy & Infertility, Sleep Management, Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 3 locations

Study Locations

Hide all locations
Location
Carlisle, PA
Harrisburg, PA
Hershey, PA

Walking through the forests of the future: Using data-driven iVR to visualize forests under climate change

We used a combination of ecological modeling, procedural modeling, and virtual reality to provide an embodied experience of “walking through the forests of the future”. This study will provide empirical evidence of the effectiveness of this immersive experience based on users’ feedbacks on different kinds of tools we developed.
Jiawei Huang at jzh87@psu.edu or 734-355-5327
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
forestry or climate science related majors (include but not limited to agricultural sciences, environmental resources management, forest ecosystem management, plant science, ecology, biology, meteorology and atmospheric science)
undergraduate or graduate students at Penn State University who are older than 18.
participants should be healthy (without contagious disease)
Exclusion Criteria:
people under 18
people who are cognitively impaired
people who have contagious disease
Education, Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

"Alexa, I’m in pain! "A Real-Time Mindfulness Intervention to Control Pain: Delivery Through a Conversational Agent

We are interested in learning about people’s experiences with using the Amazon Alexa for delivery of a real-time mindfulness intervention to help with chronic pain management. Participation will include a free day-long introductory mindfulness training followed by daily use of mindfulness practices using the Amazon Alexa to establish a habit of use. The participants will use our developed Amazon Alexa app ("skill") and provide assessments. We will ask participants to complete short daily surveys and a follow-up interview.
Sebrina Doyle at sld40@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals who had some experience with chronic pain over the last 6 months
Living in homes with internet access
Willing to use a smart-home device (Amazon Alexa)
Have access to a smart phone
Read, write, and speak English
Exclusion Criteria:
Under 18 years old
Major mental health issue that is not currently under advisement of a doctor/therapist
Actively struggling with addiction to substances or newly in recovery
Participants who currently report using mindfulness practices more than 1x a month
Pain Management
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis

This study is for patients diagnosed with non-alcoholic steatohepatitis or NASH, which is a type of liver disease known as fatty liver. This research is being done to find out how safe and effective an experimental medication is when compared to a placebo for the treatment of liver fibrosis in patients with NASH. A placebo looks like the study drug but does not contain the study drug’s active ingredient.
Laurie Peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03028740
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-75 years of age
Diagnosed with Non-Alcoholic Steatohepatitis (NASH) or fatty liver
No new treatment for NASH in the past 6 months
Exclusion Criteria:
Hepatitis B or C
HIV
Prior or planned liver transplant
Other known causes of chronic liver disease such as cirrhosis
Weight reduction through bariatric surgery in the past 5 years or planned
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA